Ultradian Diagnostics represents a unique investment opportunity for early-stage investors. On October 25, 2011, Ultradian Diagnostics successfully completed an initial 15 subject 12-hour in-clinic pilot study at SUNY Upstate Medical University. The Company was able to achieve this significant milestone for less than $2.5M in equity investment.
The Company operates in a cost-efficient manner to offer investors attractive returns on their investment. Furthermore, the Company possesses the technical know-how and business vision to successfully develop cutting edge technical solutions for critical unmet market needs at a fraction of the cost of our larger competitors.
Ultradian Diagnostics is actively seeking strategic partnerships to integrate the Biologue CGM with an insulin pump to create an “artificial pancreas”, and to advance the minimally and non-invasive diagnostic capabilities of the Biologue platform into cardiology, sports medicine, and military applications.
Ultradian has active collaborations with universities allowing us to gain third party validation of the Biologue CGM and advance the technology beyond the prototype phase of development:
Ultradian Diagnostics is the recipient of state and federal funds to demonstrate proof of concept and advance the Biologue CGM to the clinical phase of development:
Internal Revenue Service/Department of Health and Human Services Qualifying Therapeutic Discovery Program (QTDP)
If you are interested in learning more about Ultradian Diagnostics, please contact our CEO directly at firstname.lastname@example.org or 518-618-0046.